CN112716982B - Lactic acid bacteria-containing composition and use thereof - Google Patents
Lactic acid bacteria-containing composition and use thereof Download PDFInfo
- Publication number
- CN112716982B CN112716982B CN201910973576.9A CN201910973576A CN112716982B CN 112716982 B CN112716982 B CN 112716982B CN 201910973576 A CN201910973576 A CN 201910973576A CN 112716982 B CN112716982 B CN 112716982B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- composition
- group
- powder
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims description 44
- 241000894006 Bacteria Species 0.000 title claims description 28
- 239000004310 lactic acid Substances 0.000 title claims description 22
- 235000014655 lactic acid Nutrition 0.000 title claims description 22
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 35
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 33
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 33
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 33
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 33
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 33
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 33
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 32
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 32
- 229920002261 Corn starch Polymers 0.000 claims abstract description 31
- 239000008120 corn starch Substances 0.000 claims abstract description 31
- 229920001353 Dextrin Polymers 0.000 claims abstract description 30
- 239000004375 Dextrin Substances 0.000 claims abstract description 30
- 235000019425 dextrin Nutrition 0.000 claims abstract description 30
- 229920001202 Inulin Polymers 0.000 claims abstract description 29
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 29
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 29
- 229940029339 inulin Drugs 0.000 claims abstract description 29
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 29
- 241000186660 Lactobacillus Species 0.000 claims abstract description 27
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 27
- 208000004998 Abdominal Pain Diseases 0.000 claims abstract description 14
- 206010000060 Abdominal distension Diseases 0.000 claims abstract description 14
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 12
- 230000000968 intestinal effect Effects 0.000 claims abstract description 10
- 206010010774 Constipation Diseases 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 65
- 235000013399 edible fruits Nutrition 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 15
- 238000004321 preservation Methods 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 8
- 240000009088 Fragaria x ananassa Species 0.000 claims description 8
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 5
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 5
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 5
- 235000004634 cranberry Nutrition 0.000 claims description 5
- 229940045731 elderberry fruit Drugs 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 44
- 229920002774 Maltodextrin Polymers 0.000 abstract description 29
- 239000005913 Maltodextrin Substances 0.000 abstract description 29
- 229940035034 maltodextrin Drugs 0.000 abstract description 29
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract description 21
- 229960001243 orlistat Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 15
- 235000019640 taste Nutrition 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 229940099112 cornstarch Drugs 0.000 abstract description 2
- 230000009982 effect on human Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 206010013082 Discomfort Diseases 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 51
- 238000000034 method Methods 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 229940079593 drug Drugs 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 235000013305 food Nutrition 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 4
- 229950002397 cetilistat Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960002599 rifapentine Drugs 0.000 description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 zymonin Chemical compound 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- UJOHNXQDVUADCG-UHFFFAOYSA-L aluminum;magnesium;carbonate Chemical compound [Mg+2].[Al+3].[O-]C([O-])=O UJOHNXQDVUADCG-UHFFFAOYSA-L 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition containing lactobacillus and application thereof, wherein the composition contains lactobacillus plantarum, lactobacillus acidophilus, lactobacillus paracasei, bifidobacterium bifidum, resistant dextrin, maltodextrin, corn starch, inulin, stachyose and other components. Animal model tests show that the composition has the effects of regulating intestinal microecological balance, remarkably improving abdominal pain, abdominal distension, diarrhea and constipation, and relieving various discomforts caused by orlistat administration. The composition has simple preparation process and is suitable for industrial production. The product has good taste, easy digestion, no side effect on human body, and high safety.
Description
Technical Field
The invention relates to the field of food, relates to a composition containing lactobacillus and application thereof, and particularly relates to a preparation composition and application of instant lactobacillus.
Background
Lactic acid bacteria are one kind of probiotics and can regulate the composition of some part of the host's flora to form active microbes beneficial to the host. The intestinal health is maintained by regulating the immune function of host mucous membrane and system or by regulating the flora balance in intestinal tract, so that single microorganism or mixed microorganism with definite composition beneficial to the health of the host is generated.
Lactic Acid Bacteria (LAB), a probiotic bacterium present in the human body, are a general term for a group of bacteria that can produce a large amount of lactic acid using fermentable carbohydrates, and can help digestion and health of the human intestine. A large number of researches show that the probiotic lactic acid bacteria can regulate normal flora of gastrointestinal tracts of organisms, keep micro-ecological balance, improve the digestibility and the biovalue of food, reduce serum cholesterol, control endotoxin, inhibit growth and propagation of putrefying bacteria and generation of putrefying products in intestinal tracts, produce nutrient substances and stimulate tissue development, thereby having effects on the nutritional state, the physiological function, cell infection, drug effect, toxic reaction, immune reaction, tumorigenesis, aging process, sudden emergency reaction and the like of the organisms. The probiotic lactic acid bacteria not only can improve the nutritive value of food, improve the flavor of food and improve the preservation property and added value of food, but also increasingly attract attention from people on the special physiological activity and nutritional function of the probiotic lactic acid bacteria.
Orlistat was developed by the global famous pharmaceutical enterprise rochon in 1998, is a novel gastrointestinal lipase inhibitor, is mainly used for treating patients with excessive body mass and obesity clinically at present, has anti-tumor activity in research confirmation, and is an OTC (over the counter) weight-reducing drug which is the only global weight-reducing drug at present and is also the only weight-reducing drug approved by the FDA (food and drug administration) and the food and drug administration of China. Orlistat is a long-acting and potent inhibitor of Fatty Acid Synthase (FAS), which is not only a key enzyme in the synthesis of fatty acids, but also plays an important role in obesity, embryonic development, and tumor development. Cetilistat is a long-acting and potent specific gastrointestinal lipase inhibitor that exerts its therapeutic effect by inactivating enzymes that are unable to hydrolyze fats in food, primarily triglycerides, to absorbable free fatty acids and monoacylglycerols by forming covalent bonds with the active serine sites of gastric and pancreatic lipases in the gastric and small intestinal lumens. Undigested triglycerides are not absorbed by the body, thereby reducing caloric intake, controlling body weight, and the drug does not act on the nervous system, does not affect other enzymatic activities of the gastrointestinal tract, does not suppress appetite, and does not require dietary restrictions. Many drugs such as these are easy to leak oil, abdominal pain, abdominal distension, diarrhea, constipation, etc. when taken.
Disclosure of Invention
In view of the above, the present invention provides a composition containing lactic acid bacteria, which can be prepared into an instant lactic acid bacteria, and can be used for treating abdominal pain, abdominal distension, diarrhea and other diseases by being taken alone, and can be taken together with other medicines, such as orlistat, cetilistat and the like, to promote the weight-reducing effect of the composition, and reduce the occurrence of side effects of the medicines.
Specifically, the invention is realized by the following steps:
a lactobacillus-containing strain, which comprises at least one selected from Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, Bifidobacterium bifidum TMC 3115. According to weight ratio, the lactobacillus plantarum LP45 is 0.1-10 parts, the lactobacillus acidophilus La28 is 0.01-10 parts, the lactobacillus paracasei YMC1069 is 0.01-10 parts, and the bifidobacterium bifidum TMC3115 is 0.01-10 parts.
The lactobacillus plantarum LP45 is preserved in China general microbiological culture collection center, and is preserved in Beijing province of south-rising district, Xilu No.1 Hospital, with the preservation date of 2013, 8 months and 26 days as follows: CGMCC No. 8072.
Lactobacillus acidophilus La28, which is preserved in China general microbiological culture Collection center at the preservation address of No. 3 of the Xilu No.1 of the North Chen of the Chaoyang district, Beijing, the microbial research institute of the Chinese academy of sciences, with the preservation date of 2015, 10 months and 15 days and the preservation number of CGMCC No. 11506.
Bifidobacterium bifidum TMC3115, which is preserved in China general microbiological culture Collection center with the preservation date of 2013, 11 months and 11 days, and the preservation number is CGMCC No.8462, wherein the culture is collected at the institute of microorganisms of Zhongkou institute, West Lu No.1 Hospital, Tokyo, south-facing-Yang district, Beijing.
Lactobacillus paracasei YMC1069, which is preserved in the China general microbiological culture Collection center of the China Committee for culture Collection of microorganisms, with the address of the institute of microbiology of Zhongkoyao, West Lu No.1 Hospital, Chaozhou, the south Korean district, the preservation date of 2019, 10 months and 14 days, and the preservation number of CGMCC No. 18676.
The strain at least comprises two strains selected from Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069 and Bifidobacterium bifidum TMC 3115.
The strain at least comprises three strains selected from Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069 and Bifidobacterium bifidum TMC 3115.
The strain comprises lactobacillus plantarum LP45, lactobacillus acidophilus La28, lactobacillus paracasei YMC1069 and bifidobacterium bifidum TMC 3115.
A composition a comprising the following ingredients: a) comprising the strain of any one of claims 1 to 5; and b) one or both of inulin and stachyose; and/or c) any one or more of powder and adhesive.
The powder is selected from one or more of starch, dextrin, flavoring agent, fruit powder, plant extract and food additive; the adhesive is selected from any one of corn starch, wheat starch, soybean starch and food acceptable adhesive.
The powder is selected from 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 15-40 parts of inulin and 1-10 parts of stachyose, and the adhesive is corn starch 10-30 parts.
Further, the composition A containing the lactic acid bacteria comprises the following components in percentage by weight: 0.1-10 parts of lactobacillus plantarum, 0.01-10 parts of lactobacillus acidophilus, 0.01-10 parts of lactobacillus paracasei, 0.01-10 parts of bifidobacterium bifidum, 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 10-30 parts of corn starch, 15-40 parts of inulin and 1-10 parts of stachyose.
Preferably, the composition comprises, by weight: 2.5 parts of lactobacillus plantarum, 0.6 part of lactobacillus acidophilus, 0.1 part of lactobacillus paracasei, 0.1 part of bifidobacterium bifidum, 28.34 parts of resistant dextrin, 16.54 parts of maltodextrin, 19.85 parts of corn starch, 26.46 parts of inulin and 5.51 parts of stachyose.
The composition may also contain fruit powder. The fruit powder is one or more of fructus Citri Junoris powder, caulis et folium Sambuci Williamsii fruit powder, cranberry fruit powder, and strawberry fruit powder;
preferably, the composition of the composition A comprises the following components in percentage by weight: 451-4 parts of lactobacillus plantarum LP, 1.1-1 part of lactobacillus acidophilus La280, 1-1 part of lactobacillus paracasei YMC 10690.01, 31150.01-1 part of bifidobacterium bifidum TMC, 20-30 parts of resistant dextrin, 10-20 parts of maltodextrin, 15-25 parts of corn starch, 20-30 parts of inulin, 1-10 parts of stachyose and 5-10 parts of fruit powder.
Preferably, the composition of the composition A comprises the following components in percentage by weight: lactobacillus plantarum LP 452.5 parts, Lactobacillus acidophilus La280.6 parts, Lactobacillus paracasei YMC 10690.1 parts, Bifidobacterium bifidum TMC 31150.1 parts, resistant dextrin 26.6 parts, maltodextrin 15.5 parts, corn starch 18.6 parts, inulin 24.8 parts, stachyose 5.2 parts and fruit powder 6.0 parts.
Preferably, the composition of the composition A comprises the following components in percentage by weight: the fruit powder comprises, by weight, 452.5 parts of lactobacillus plantarum LP, 280.6 parts of lactobacillus acidophilus La280, 10690.1 parts of lactobacillus paracasei YMC, 31150.1 parts of bifidobacterium bifidum TMC, 25.7 parts of resistant dextrin, 15.0 parts of maltodextrin, 18.0 parts of corn starch, 24.0 parts of inulin, 5.0 parts of stachyose and 9.0 parts of fruit powder.
The lactic acid bacteria-containing composition A is an instant lactic acid bacteria, can be used alone or in combination with any one of medicines which are easy to cause oil leakage, abdominal pain, abdominal distension and diarrhea, and has the effects of remarkably improving oil leakage, abdominal pain, abdominal distension, diarrhea and constipation, improving intestinal microcirculation, functional dyspepsia and the like.
Further, the drug is selected from the group consisting of diarrhea caused by sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampin, rifapentine, fluorouracil antineoplastic drugs, and abdominal pain caused by neostigmine, physostigmine, zymonin, mecamylamine, hexamine, atropine, chlorpromazine, tricyclic antidepressants, diphenhydramine. When the above drugs are taken, the composition of the present invention is taken at intervals of at least 2 hours.
Further, the drug is selected from orlistat and cetilistat, and can be taken together with the composition of the present invention.
A composition B, said composition I comprising:
a) ready-to-eat lactic acid bacteria and
b) orlistat, new libestat, baking soda, aluminium hydroxide, aluminium magnesium carbonate, amoxicillin, irinotecan, isoniazid, rifampin, rifapentine, fluorouracil antineoplastic arbitrary one prepare into the composite to use jointly or arbitrary one uses jointly.
The preparation product is characterized by being selected from any one of tablets, capsules, granules, powder, pills, oral liquid and soft capsules. The preparation product contains the bacterial strain or the composition A or the composition B.
The composition A is an instant lactobacillus, and is a food.
The composition of the invention comprises at least 10 per g dry weight 6 To 10 12 CFU bacteria/g composition.
The composition of the invention comprises at least 10 per g dry weight 8 To 10 11 CFU bacteria/g composition.
The use of a strain according to the invention for the preparation of a food product for preventing and/or alleviating gastrointestinal discomfort or gastrointestinal disease.
Use of the strain according to the invention for the preparation of a food product for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
Use of a composition a according to the invention for the preparation of a food product for the prevention and/or alleviation of gastrointestinal disorders or diseases.
The composition A is used for preparing a food product for improving gastrointestinal motility, improving intestinal peristalsis and/or reducing intestinal permeability.
The invention also provides application of the composition A in preparing a medicine for preventing and/or relieving gastrointestinal discomfort or gastrointestinal diseases.
The composition A is used for preparing a medicine for improving gastrointestinal motility, improving intestinal peristalsis and/or reducing intestinal permeability.
An application of the combination of instant lactobacillus and orlistat in losing weight, improving oil leakage, abdominal pain, abdominal distension, diarrhea and constipation, and improving intestinal microenvironment.
Human body tests show that after the composition A is taken, orlistat and cetilistat can not bring oily substances in qi-passing state, thereby avoiding embarrassment.
In addition, the strain, the composition A or the composition B can be combined with auxiliary materials to be prepared into tablets, capsules, granules, powder, pills, oral liquid and soft capsules.
Another objective of the present invention is to provide a method for preparing instant lactic acid bacteria, wherein the process flow of the method is shown in FIG. 1.
Mixing lactobacillus plantarum, lactobacillus acidophilus, lactobacillus paracasei and bifidobacterium bifidum with the formula amount, resistant dextrin, maltodextrin, corn starch, inulin, stachyose and fruit powder uniformly to obtain bacterium powder, and bagging to obtain the product;
more specifically, the method comprises the following steps:
(1) preparing a prescription amount of corn starch into an adhesive, and uniformly mixing the prescription amount of lactobacillus plantarum, lactobacillus acidophilus, lactobacillus paracasei and bifidobacterium bifidum into bacterial powder for later use;
(2) taking the resistant dextrin, the maltodextrin, the inulin, the stachyose and the fruit powder according to the prescription amount, and uniformly stirring and mixing to prepare a mixture; spraying binder, granulating, sterilizing, sieving, and mixing with the powder.
In animal model experiments, the instant lactic acid bacteria have the effects of adjusting intestinal microecological balance, remarkably improving or relieving abdominal pain, abdominal distension, diarrhea and constipation, and are beneficial to normal defecation, safe detoxification and improvement of organism immunity.
The product has good taste and easy digestion, and can be made into various foods according to different tastes of people. The safety is high, and the adopted lactic acid bacteria are edible materials, so that the lactic acid bacteria have no side effect on human bodies and can be accepted by consumers. Some people worry about that the weight-losing effect cannot be achieved by reducing oil discharge, which is the improvement of the intestinal microenvironment by the composition, and the weight-losing effect cannot be affected by taking the composition and the orlistat product through detecting the weight of a subject, and some trial participants also feed back that the weight is reduced after taking the trial for 1 week. Also, the test subjects did not gain weight by ingesting a high oil diet within a week.
Description of the drawings:
FIG. 1 is a process flow chart of the preparation method of the instant lactic acid bacteria.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further described below by way of specific examples, but the present invention is not limited to the following examples, and any equivalent substitutions in any form will be apparent to those of ordinary skill in the art and are included in the present invention.
Example 1: a composition A containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: 450.1 g of lactobacillus plantarum LP, 280.01 g of lactobacillus acidophilus La280, 10690.01 g of lactobacillus paracasei YMC, 31150.01 g of bifidobacterium bifidum TMC, 15 g of resistant dextrin, 10 g of maltodextrin, 10 g of corn starch, 15 g of inulin and 1 g of stachyose.
The preparation process comprises the following steps:
(1) preparing a binding agent by taking the corn starch with the prescription amount, and uniformly mixing the lactobacillus plantarum, the lactobacillus acidophilus and the lactobacillus paracasei with the prescription amount to obtain bacterial powder for later use;
(2) taking the prescription dose of the resistant dextrin, the maltodextrin, the corn starch, the inulin, the stachyose and the fruit powder, and uniformly stirring and mixing to prepare a mixture; spraying binder, granulating, sterilizing, sieving, and mixing with the powder.
Example 2: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 4510 g, lactobacillus acidophilus La 2810 g, lactobacillus paracasei YMC 106910 g, bifidobacterium bifidum TMC 311510 g, resistant dextrin 35 g, maltodextrin 30 g, corn starch 30 g, inulin 40 g, stachyose 10 g.
The preparation process is the same as in example 1.
Example 3: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 452.5 g, Lactobacillus acidophilus La280.6 g, Lactobacillus paracasei YMC 10690.1 g, Bifidobacterium bifidum TMC 31150.1 g, resistant dextrin 28.34 g, maltodextrin 16.54 g, corn starch 19.85 g, inulin 26.46 g, stachyose 5.51 g.
The preparation process is the same as in example 1.
Example 4: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: 451 g of lactobacillus plantarum LP, 281 g of lactobacillus acidophilus La, 10691 g of lactobacillus paracasei YMC, 31151 g of bifidobacterium bifidum TMC, 20g of resistant dextrin, 10 g of maltodextrin, 15 g of corn starch, 20g of inulin, 1 g of stachyose and 5 g of orange fruit powder.
The preparation process is the same as in example 1.
Example 5: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 454 g, Lactobacillus acidophilus La 281 g, Lactobacillus paracasei YMC 10691 g, Bifidobacterium bifidum TMC 31151 g, resistant dextrin 30 g, maltodextrin 20g, corn starch 25 g, inulin 30 g, stachyose 10 g and orange fruit powder 10 g.
The preparation process is the same as in example 1.
Example 6: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: 451 g of lactobacillus plantarum LP, 281 g of lactobacillus acidophilus La, 10691 g of lactobacillus paracasei YMC, 31151 g of bifidobacterium bifidum TMC, 20g of resistant dextrin, 10 g of maltodextrin, 15 g of corn starch, 20g of inulin, 1 g of stachyose and 5 g of elderberry fruit powder.
The preparation process is the same as in example 1.
Example 7: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 454 g, Lactobacillus acidophilus La 281 g, Lactobacillus paracasei YMC 10691 g, Bifidobacterium bifidum TMC 31151 g, resistant dextrin 30 g, maltodextrin 20g, corn starch 25 g, inulin 30 g, stachyose 10 g and elderberry fruit powder 10 g.
Example 8: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 452.5 g, Lactobacillus acidophilus La280.6 g, Lactobacillus paracasei YMC 10690.1 g, Bifidobacterium bifidum TMC 31150.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, and cranberry fruit powder 6.0 g.
The preparation process is the same as in example 1.
Example 9: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: the milk powder is prepared from the following raw materials, by weight, 452.5 g of lactobacillus plantarum LP, 280.6 g of lactobacillus acidophilus La280, 10690.1 g of lactobacillus paracasei YMC, 31150.1 g of bifidobacterium bifidum TMC, 25.7 g of resistant dextrin, 15.0 g of maltodextrin, 18.0 g of corn starch, 24.0 g of inulin, 5.0 g of stachyose and 9.0 g of strawberry fruit powder.
The preparation process is the same as in example 1.
Example 10: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 452.5 g, Lactobacillus acidophilus La280.6 g, Lactobacillus paracasei YMC 10690.1 g, Bifidobacterium bifidum TMC 31150.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, and cranberry fruit powder 6.0 g.
The preparation process was the same as in example 1, and the above-mentioned raw materials were prepared into capsules each containing 500mg of the raw materials by a conventional process.
Example 11: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: the milk powder is prepared from the following raw materials, by weight, 452.5 g of lactobacillus plantarum LP, 280.6 g of lactobacillus acidophilus La280, 10690.1 g of lactobacillus paracasei YMC, 31150.1 g of bifidobacterium bifidum TMC, 25.7 g of resistant dextrin, 15.0 g of maltodextrin, 18.0 g of corn starch, 24.0 g of inulin, 5.0 g of stachyose and 9.0 g of strawberry fruit powder.
The preparation process was the same as in example 1, and the above-mentioned raw materials were prepared into capsules each containing 500mg of the raw material by a conventional process.
Example 12: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 452.5 g, Lactobacillus acidophilus La280.6 g, Lactobacillus paracasei YMC 10690.1 g, Bifidobacterium bifidum TMC 31150.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, and cranberry fruit powder 6.0 g.
The preparation process was the same as in example 1, and the above-mentioned raw materials were prepared into tablets each containing 750mg of the raw material by a conventional process.
Example 13: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: the milk powder is prepared from the following raw materials, by weight, 452.5 g of lactobacillus plantarum LP, 280.6 g of lactobacillus acidophilus La280, 10690.1 g of lactobacillus paracasei YMC, 31150.1 g of bifidobacterium bifidum TMC, 25.7 g of resistant dextrin, 15.0 g of maltodextrin, 18.0 g of corn starch, 24.0 g of inulin, 5.0 g of stachyose and 9.0 g of strawberry fruit powder.
The preparation process was the same as in example 1, and the above-mentioned raw materials were prepared into tablets each containing 750mg of the raw material by a conventional process.
Example 14: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: the milk powder is prepared from the following raw materials, by weight, 452.5 g of lactobacillus plantarum LP, 280.6 g of lactobacillus acidophilus La280, 10690.1 g of lactobacillus paracasei YMC, 31150.1 g of bifidobacterium bifidum TMC, 26.6 g of resistant dextrin, 15.5 g of maltodextrin, 18.6 g of corn starch, 24.8 g of inulin, 5.2 g of stachyose and 6.0 g of strawberry fruit powder.
The preparation process is the same as in example 1.
Example 15: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus plantarum LP 452.5 g, lactobacillus acidophilus La280.6 g, lactobacillus paracasei YMC 10690.1 g, bifidobacterium bifidum TMC 31150.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g and elderberry fruit powder 6.0 g.
The preparation process is the same as in example 1.
Example 16: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus paracasei YMC 10693.3 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g and strawberry fruit powder 9.0 g.
The preparation process is the same as in example 1.
Example 17: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: lactobacillus paracasei YMC 10693.3 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, and strawberry fruit powder 9.0 g.
Example 18: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: 452.5 g of lactobacillus plantarum, 280.6 g of lactobacillus acidophilus La280.6 g, 10690.1 g of lactobacillus paracasei YMC and 31150.1 g of bifidobacterium bifidum TMC.
The preparation process is the same as in example 1.
Comparative example 1: a composition containing lactobacillus comprises the following raw materials and preparation process:
the raw materials comprise the following components in percentage by weight: 26.6 g of resistant dextrin, 15.5 g of maltodextrin, 18.6 g of corn starch, 24.8 g of inulin, 5.2 g of stachyose and 6.0 g of elderberry fruit powder.
The preparation process is the same as in example 1.
Verification of the examples:
1) the composition of the invention has the functions of improving and relieving oil leakage
1. Materials and methods
Experimental unit: shandong New Times pharmaceutical Co Ltd
Animals: kunming breed pure-line mice are provided by Lunan pharmaceutical group, Inc., and the batch number of the animal qualification certificate is as follows:
SYXK 20180008, male and female halves, 3-4 weeks old, with a body weight of 16-20 g.
The compositions/drugs involved in the experiment: the compositions of example 1, example 2, example 3, example 8, example 9, example 16, example 17, example 18, orlistat capsules (Shandong New time pharmaceutical Co., Ltd., batch No. 085190604).
The experimental method comprises the following steps: after the withdrawal, the mice are raised for one week and adapted to the environment, the mice are randomly grouped into 10 groups and 11 groups, wherein the groups are divided into a group A, a group B, a group C, a group D, a group E, a group F, a group G and a group H, the mice are continuously fed with high-fat nutrition feed (prepared by the following formula: maltodextrin 20%, casein 22%, lard 22%, sucrose 13%, milk powder 7%, peanut 9%, egg 9%, sesame oil 1% and salt 1%) for 2 days and are respectively fed with orlistat drugs (the dose is 0.78 mg/day/gavage), and the products of example 1, example 2, example 3, example 8, example 9, example 16, example 17 and example 18 (the dose is 23.4 mg/day/gavage) are respectively fed at the same time with the orlistat; group a takes orlistat and normal saline (the dosage is 23.4 mg/day/intragastric) at the same time, and continuously feeds high fat nutrition feed; normal saline (taking dose of 23.4 mg/day/intragastric administration) is fed to mice in group b, normal feed (non-high fat nutrition feed) is fed to mice in group c, normal saline (taking dose of 23.4 mg/day/intragastric administration) is fed to mice in group c, and high fat nutrition feed is continuously fed to mice in group c.
Detection indexes are as follows: after continuously feeding the mice for 3 days, the number of the grains of the feces, the shape/weight (dry weight) of the feces, the cleanliness of the posterior trunk (oil leakage) and the body weight of the mice in each group were observed. Net posterior trunk: the net degree of the posterior trunk reflects the oil leakage phenomenon of the mouse from the lateral side, generally speaking, the mouse is completely driven for 5 minutes, cleaner for 3 minutes, generally 1 minute and 0 minute different.
Statistical treatment: all experimental data are expressed as mean ± standard deviation and tested for inter-group significance t using the sps 19.0 software.
2. Results and analysis
TABLE 1 measurement results of various indexes of examples
Note: compared with the group a, the method has the advantages that, @ P＜0.05， # p is less than 0.01; compared with the group c, the P is less than 0.05, ％ P＜0.01
in comparison with the group H,&P＜0.05， * P＜0.01。
as can be seen from the table 1, after the group a is taken with orlistat while taking the high-fat feed, oil leakage and defecation are not formed, and compared with the group A-H, the group A has significant difference (P is less than 0.01); compared with the group c, the group b can see that the weight can be obviously reduced by taking orlistat, the weight-losing effect is very exact, although the stool of the group c is formed, the stool is probably the feeding reason of high-fat feed, the group A-H is superior to the group a in the aspects of the number of defecation granules, the weight (dry weight) of the stool and the weight, and the significant difference (P is less than 0.01) is realized, which indicates that the combined use of the orlistat and the product of the invention and the orlistat only have good effect.
2) Improvement and mitigation of oxazolone colitis mouse model by compositions of the invention
Colitis shows symptoms such as pain, abdominal distension, diarrhea and the like in clinic, so the experiment verifies the effect of various compositions in the embodiment of the invention by constructing a mouse colitis animal model experiment and performs related pharmacodynamic analysis. The method comprises the following specific steps:
1. materials and methods
Experimental unit: shandong New era pharmaceutical Co Ltd
Animals: kunming breed pure-line mice are provided by Lunan pharmaceutical group, Inc., and the batch number of the animal qualification certificate is as follows:
SYXK 20180008, male and female halves, 3-4 weeks old, with a body weight of 16-20 g.
The compositions/drugs involved in the experiment: the products of example 1, example 2, example 3, example 8, example 9, example 16, example 17 and example 18, orlistat capsules (Shandong New times pharmaceutical Co., Ltd., batch No. 085190604), enteritis Ning tablets (Jiangxiang Shiyang pharmaceutical Co., Ltd.).
The animal modeling method comprises the following steps: after the oxazolidinone is coated, the local skin of the mouse is inflamed, and after 5 days, the mouse is clysted again and is given with a small dose of oxazolidinone to quickly generate intestinal inflammation, so that a colitis model of the mouse is established. Specifically, after being bought back, the mice were bred for one week and adapted to the environment, the mice were randomly divided into 10 groups, 10 groups were divided into groups A, B, C, D, E, F and G, the Kunming mice were subjected to intramuscular injection, to rapid sleep anesthesia, to abdominal skin shaving (1.5 cm. times.1.5 cm), to skin painting with 0.2ml of 3% oxazolone (dissolved in 100% ethanol) for 1 day, to repeated painting for 1 time, to 5 days, to insert a silicone tube with a diameter of 2mm into the intestinal tract of the mice from the anus to a depth of about 4cm, to inject 0.15ml of oxazolone (dissolved in 50% ethanol), and to complete mouse modeling after 72 hours. In addition, 10 mice were shaved on the abdominal skin (1.5 cm. times.1.5 cm), and then applied with physiological saline, 5 days later, a silicone tube having a diameter of 2mm was inserted into the intestinal tract of the mice from the anus to a depth of about 4cm, and then 0.15ml of physiological saline was injected.
The experimental method comprises the following steps: group a, group B, group C, group D, group E, group F, group G, group H, the products of example 1, example 2, example 3, example 8, example 9, example 16, example 17, example 18 were taken (at a dose of 23.4 mg/day/gavage), respectively; the group a was administered with tablets for enteritis (administration dose: 9.8 mg/day/gavage) for 4 days continuously, the group b was administered with starch (dose: 23.4 mg/day/gavage), the group c was sham operated, and the treatment results were observed after 5 days.
Detection indexes are as follows: diarrhea and pain. The most obvious manifestation of the colitis is diarrhea, namely the frequency of the stools, which is the result most capable of visually reflecting the colitis, and the stool frequency of the mice in 24 hours is counted by the test of the invention; another characterization of colitis is pain, by the inventors observing the number of body torsions of the mice within 8h, which is one half turn or more than one. Body weight change (body weight after 5 days-body weight before experiment) and the measurement results of each group of measurement indexes are shown in table 2.
And (3) statistical treatment: all experimental data are expressed as means ± standard deviation, and a t-test for significance between groups was performed using the sps 19.0 software.
TABLE 2 measurement results of various indexes of examples
| Group of | Weight change (g) | Stool times (times/24 h) | Number of body torsions (times/8 h) |
| Group A | 9.8±3.5 @ | 2.1±1.4 @▲ | 3.56±1.38 @▲ |
| Group B | 9.9±5.0 @ | 2.2±1.7 @▲ | 3.77±2.01 @▲ |
| Group C | 10.4±3.7 @▲ | 1.6±2.0 @▲ | 2.17±4.14 @▲ |
| Group D | 10.6±3.8 @▲ | 1.7±2.2 @▲ | 1.99±1.23 @▲ |
| Group E | 11.1±7.2 @▲ | 1.7±1.9 @▲ | 1.87±1.51 @▲ |
| Group F | 9.59±3.23 @ | 2.2±1.5 @▲ | 3.91±2.36 @▲ |
| Group G | 9.08±5.26 @ | 2.1±0.9 @▲ | 3.79±1.67 @▲ |
| Group H | 9.64±6.13 @ | 2.0±0.7 @▲ | 3.63±1.93 @▲ |
| Group a | 6.2±5.7 @ | 4.0±4.4 # | 8.32±2.66 @ |
| Group b | -5.2±3.2 | 7.4±2.9 | 20.69±7.12 |
| Group c | 7.1±2.2 @ | 2.1±1.5 @▲ | 0.56±1.27 @▲ |
Note: in comparison with the group b, # P＜0.05， @ p is less than 0.01; compared with the group a, the method has the advantages that, ▲ P＜0.05。
the results in Table 2 show the body weight, stool frequency and body torsion frequency of the mice, and the model modeling is successful as shown by comparing the group b with the group b. The A group, the B group, the C group, the D group, the E group, the F group, the G group and the H group can all play a very obvious role in treatment, and the treatment is mainly characterized by obviously improving the weight and reducing the stool frequency and the pain frequency, but the overall effect of the C group, the D group and the E group is better than that of the A group, the B group, the E group, the F group and the H group, which is probably the effect difference caused by the change of the weight parts of the raw materials. The stool frequency, pain A group, pain B group, pain C group, pain D group, pain E group, pain F group, pain G group and pain H group have significant differences compared with the pain a group, which shows that the composition has definite effect and is suitable for popularization and application.
3) Human body test
According to the principle of volunteering, 110 employees of Lunan pharmaceutical group, Inc. are selected, half of the employees are male and female, 10 persons are in each group, the groups are divided into 11 groups, no difference exists among the groups in weight, age, health state and the like, and then the tests of body mouth sensitivity, smell, oil leakage, exhaust reduction, defecation smoothness, abdominal pain, borborygmus and abdominal distension are performed.
Experimental products: example 3, example 8, example 9, example 14, example 15, example 16, example 17, example 18, comparative example 1, orlistat capsules (Shandong New times pharmaceutical industry Co., Ltd.; Specification: 100mg, production batch: 085190604-; 085190607)
And (3) inclusion standard: body Mass Index (BMI) is above 24, and SulEr Jia is taken alone for 1-2 days, and oil discharge occurs and lasts for 1-2 days.
The method comprises the following steps: after eating 1 orlistat capsule in a high-fat high-energy meal (noon and afternoon) for 7 days in a unified manner by Shandong New epoch pharmaceutical Co., Ltd,
9 grams of each of the products of example 14, example 15, example 16, example 17, and example 18 were given to the control group, which was given 9 grams of starch. The combination is administered for 5-6 days in a cycle of 7 days.
Detection indexes are as follows:
1) degree of mouthfeel: the satisfaction of the taste of taking the composition of the invention is as follows: very satisfactory 10 points, satisfactory 7 points, generally 3 points, and 1 point difference.
2) Oil leakage: degree of reduction of oil leakage at the time of passing qi: very satisfactory 10 points, satisfactory 7 points, generally 3 points, and 1 point difference.
3) Odor: the faint scent degree of the composition of the invention: very satisfactory 10 points, satisfactory 7 points, generally 3 points, and 1 point difference.
4) Exhaust gas reduction: degree of exhaust gas reduction: very satisfactory 10 points, satisfactory 7 points, generally 3 points, and 1 point difference.
5) The defecation is smooth: very satisfactory 10 points, satisfactory 7 points, generally 3 points, and 1 point difference.
6) Abdominal pain, borborygmus, abdominal distension: the degree of alleviating the abdominal pain, the borborygmus and the abdominal distension is satisfied by 10 points, satisfied by 7 points, generally 3 points and 1 point different.
As a result: the final scores were pooled and statistically analyzed using a sps 19.0.
TABLE 3 measurement results (X. + -. S) of each index in examples
Note: in comparison with the example 3, it is shown that, # p is less than 0.05, compared with the control group @ P＜0.05， ▲ P＜0.01
In comparison with the comparative example 1, the present inventors have conducted a study, ￥ P＜0.05， & P＜0.01。
as can be seen from Table 3, the degree of taste and the smell of the added fruit powder are more easily accepted, but the problem of oil leakage can be solved as well; the comparative examples and the control group found that some were the same as or inferior to the examples of the present invention in terms of taste, and for example, the comparative example 1 was similar to the examples in terms of odor and taste, but was significantly different from the examples of the present invention in terms of solving the oil leakage.
TABLE 4 measurement results (X. + -. S) of respective indices of examples
| Exhaust reduction | Defecation is smooth and easy | Abdominal pain, borborygmus and abdominal distension | |
| Example 3 | 78.3±10.3 | 87.3±8.5 | 94.3±8.9 |
| Example 8 | 82.6±9.7 | 87.9±7.9 | 94.6±8.2 |
| Example 9 | 83.0±8.5 | 88.3±8.9 | 94.5±7.9 |
| Example 14 | 82.1±9.3 | 87.4±7.0 | 93.2±5.6 |
| Example 15 | 83.3±8.5 | 88.0±8.8 | 93.5±8.4 |
| Example 16 | 76.8±11.3 ￥ | 85.8±10.2 ▲ | 90.8±7.9 & |
| Example 17 | 77.9±11.9 | 86.6±6.9 | 91.6±10.4 |
| Example 18 | 78.6±10.2 | 87.2±9.1 | 92.3±6.6 |
| Comparative example 1 | 9.3±2.5 | 87.3±8.9 | 10.3±1.5 |
| Control group | 8.6±2.7 | 6.3±2.3 | 7.5±2.3 |
Note: compared with the control group @ P＜0.05， ▲ P is less than 0.01; in comparison with the comparative example 1, the present inventors, ￥ P＜0.05， & P＜0.01。
as can be seen from Table 4, the composition of the present invention, when applied together with orlistat, can significantly reduce the amount of exhaust air, so that the defecation process is smoother, and the phenomena of abdominal pain, borborygmus and abdominal distension are effectively relieved and improved.
4) Index determination of the composition of the invention
In order to meet the requirements of consumers, the product of the invention is detected and measured by various indexes such as sense, physicochemical, microorganism and the like, and the specific steps are as follows:
sensory measurement: color, smell, condition of the product, and whether there are foreign bodies visible to the naked eye.
TABLE 5 sensory measurement of the examples
| Color | Smell(s) | Status of state | Impurities | |
| Example 1 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 2 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 3 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 8 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 9 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 14 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 15 | Yellowish | No putrefaction and odor | Powder or granules | No foreign matter visible to naked eye |
| Example 16 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 17 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Example 18 | Yellowish | No putrefaction and odor | Powder or granules | No foreign body visible to naked eyes |
| Comparative example 1 | Yellowish | No putrefaction and odor | Powder or granules | No foreign matter visible to naked eye |
As can be seen from Table 5, comparative example 3 has no auxiliary materials, has a poor odor and a yellow color, and has impurities, probably because the auxiliary materials have a certain effect in covering the odor and degrading the impurities.
Physical and chemical indexes: the method for detecting moisture is according to the first method of GB5009.3-2016, and the method for detecting lead is according to the first method of GB 5009.12-2017.
TABLE 6 physicochemical indices of the examples
As can be seen from Table 6, the water content of each group of examples is below 1%, which is significantly better than that of the standard requirement of below 7.0, and the water content of comparative example 3 is significantly higher than that of the inventive examples without auxiliary materials.
Microorganism indexes are as follows: detecting microorganisms such as total number of lactobacillus and mould.
TABLE 7 microbiological indicators of examples 8, 9, 14, 15
As can be seen from Table 7, the total number of lactic acid bacteria was determined by GB4789.35-2016, Staphylococcus aureus GB4789.10-2016, Salmonella GB4789.4-2016, fungi GB4789.15-2016, and Escherichia coli GB 4789.3-2016. The strain content of each embodiment is more than 200 hundred million, and the strain meets the requirements related to food.
Claims (5)
1. The lactobacillus strain composition is characterized in that the strain consists of the following four bacteria: lactobacillus plantarum (Lactobacillus plantarum) LP45, accession number: CGMCC No. 8072; lactobacillus acidophilus (Lactobacillus acidophilus) La28 with the preservation number of CGMCC No. 11506; lactobacillus paracasei (Lactobacillus paracasei) YMC1069 with the preservation number of CGMCC No. 18676; bifidobacterium bifidum (Bifidobacterium bifidum) TMC3115 with preservation number CGMCC No. 8462.
2. A composition comprising a lactic acid bacterium, wherein the composition comprises the lactic acid bacterium composition of claim 1, and further comprises:
a) one or two of inulin and stachyose; and/or
b) Any one or two of powder and adhesive;
the powder is selected from any one or two of starch, dextrin and fruit powder; the adhesive is selected from any one of corn starch, wheat starch and soybean starch.
3. The composition of claim 2, wherein the fruit powder is selected from one or both of orange fruit powder, elderberry fruit powder, cranberry fruit powder, and strawberry fruit powder.
4. Use of a composition according to claim 1 or 2 for the manufacture of a medicament for improving oil leakage, abdominal pain, abdominal distension, diarrhoea, constipation, or improving the intestinal microenvironment.
5. A formulation comprising the composition of claim 1, wherein the formulation is selected from any one of a tablet, a capsule, a granule, a powder, and a soft capsule.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210665268.1A CN115074274B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
| CN201910973576.9A CN112716982B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
| PCT/CN2020/105229 WO2021073197A1 (en) | 2019-10-14 | 2020-07-28 | Composition containing lactic acid bacteria and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973576.9A CN112716982B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210665268.1A Division CN115074274B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112716982A CN112716982A (en) | 2021-04-30 |
| CN112716982B true CN112716982B (en) | 2022-09-13 |
Family
ID=75538325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910973576.9A Active CN112716982B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
| CN202210665268.1A Active CN115074274B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210665268.1A Active CN115074274B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN112716982B (en) |
| WO (1) | WO2021073197A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737672A (en) * | 2020-06-01 | 2023-03-07 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN113712200A (en) * | 2021-08-04 | 2021-11-30 | 上海楷达生物科技有限公司 | Composition for improving cardiopulmonary stress and promoting exercise recovery |
| CN114540235B (en) * | 2022-03-04 | 2023-10-31 | 中国海洋大学 | Method for inducing lactic acid bacteria to sleep and application thereof |
| CN115181695B (en) * | 2022-06-27 | 2023-08-29 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
| CN116726054B (en) * | 2022-12-05 | 2024-03-26 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
| CN116262125B (en) * | 2023-01-19 | 2023-11-14 | 哈尔滨美华生物技术股份有限公司 | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof |
| CN116235955B (en) * | 2023-05-12 | 2023-12-29 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1020123A1 (en) * | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103642716B (en) * | 2013-11-21 | 2017-02-01 | 河北一然生物科技有限公司 | Lactobacillus plantarum and application thereof |
| CN104630096B (en) * | 2014-12-16 | 2016-08-24 | 河北一然生物科技有限公司 | There is bifidobacterium bifidum TMC3115 and the application thereof of suppression adipose cell |
| CA2983083A1 (en) * | 2015-04-30 | 2016-11-03 | Probiotical S.P.A. | Use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria with a non-transferable antibiotic resistance, having the same therapeutic indication |
| CN106011006A (en) * | 2016-06-01 | 2016-10-12 | 河北然生物科技有限公司 | Lactobacillus acidophilus La28 with immunoregulation function and allergy-resisting function and applications of lactobacillus acidophilus La28 |
| CN109938249B (en) * | 2017-12-21 | 2022-06-10 | 中粮营养健康研究院有限公司 | Rice protein composition |
| CN110150669B (en) * | 2019-04-29 | 2022-09-06 | 河北一然生物科技股份有限公司 | Probiotic composition suitable for diabetic patients and application thereof |
| CN110946913B (en) * | 2019-12-17 | 2021-01-19 | 河北一然生物科技有限公司 | Probiotic composition for relieving constipation and hemorrhoids |
-
2019
- 2019-10-14 CN CN201910973576.9A patent/CN112716982B/en active Active
- 2019-10-14 CN CN202210665268.1A patent/CN115074274B/en active Active
-
2020
- 2020-07-28 WO PCT/CN2020/105229 patent/WO2021073197A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1020123A1 (en) * | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
Non-Patent Citations (2)
| Title |
|---|
| Probiotic Fermentation ofplant based products:possibilities and opportunities;Gupta S等;《Critical Reviews in Food Science and Nutrition》;20121231;第52卷(第2期);第183-199页 * |
| 蔬菜汁的乳酸菌发酵;刘锐等;《食品与发酵工业》;20130430(第04期);第114-118页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112716982A (en) | 2021-04-30 |
| CN115074274A (en) | 2022-09-20 |
| CN115074274B (en) | 2023-04-18 |
| WO2021073197A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| KR101911205B1 (en) | Composition for defecation inducement and diet and producing method thereof | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| AU2005294369A1 (en) | Synbiotics | |
| TW200902040A (en) | Probiotics in a pre-and/or post-surgical environment | |
| US20210060096A1 (en) | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances | |
| CN102665737A (en) | Bifidobacterium longum ATCC BAA-999 (BL999) and weight control | |
| CN113413406A (en) | A metazoan compound, its preparation method and application in resisting helicobacter pylori and gastrointestinal diseases | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN104432001A (en) | Edible composition and use thereof | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| CN110692885A (en) | Probiotic health-care beverage for relieving constipation | |
| Faujdar et al. | Role of probiotics in human health and disease: an update | |
| CN116942706A (en) | Application of Akkermansia muciniphila in preparation of products for preventing, treating and/or assisting in treating enteritis | |
| TW202114542A (en) | Prebiotic composition for promoting growth ofclostridium butyricumand uses thereof | |
| WO2016049883A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
| CN106479906A (en) | Butyribacter intestinalis and its application | |
| CN110771766A (en) | Probiotic health-care beverage for treating child intestinal colic and diarrhea and repairing intestinal tract | |
| US9826766B2 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| Arora et al. | Therapeutic potential of probiotics: A ray of hope or nightmare? | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN106889615B (en) | A trace element selenium dietary supplement with the function of regulating intestinal flora and its application | |
| Georgieva et al. | Probiotics: past, present, and future challenges | |
| US11278578B2 (en) | Combination probiotic compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |